PepEvolutionHow the Peptide Supply Chain Actually Works
The peptide market is intentionally opaque. Chinese factories supply both FDA-regulated pharmacies and unregulated "research" vendors, often from the same batch.Once you understand how the chain works, one question decides everything: does your vendor publish a real, independent lab test?
Where peptides come from, what 503A/503B mean, who actually tests, and why most "research" COAs are worthless.
Look up any vendor and see whether their certificates are real, recycled, failed, or missing entirely.
Every compound scored 0-100 across Evidence, Sourcing & COA, Safety, and Practicality, then banded A+ to F.
The Supply Chain
Key insight: The raw peptide material for both paths often originates from the same upstream Chinese API manufacturers, but diverges sharply in regulatory oversight and quality controls at Tier 2. That divergence is exactly why a per-batch, independently-verified COA matters more than the brand on the vial.
503A vs. 503B: What They Mean
| 503A Compounding Pharmacy | 503B Outsourcing Facility | |
|---|---|---|
| Regulator | State pharmacy board + some FDA | FDA (cGMP, federally inspected) |
| Scale | Patient-specific, small batch | Large batch, can supply clinics/hospitals |
| Prescription | Yes, per patient | Not required (office stock) |
| Peptide compounding | More flexibility if Category 1 | Essentially none, no peptides on 503B Bulks List |
| BPC-157 / TB-500 (June 2026) | Gray zone, removed from Cat. 2, not yet authorized | Even stricter, not authorized |
| Semaglutide / Tirzepatide | Prohibited since April/May 2025 | Permanently excluded (proposed April 2026) |
April 2026 milestone: FDA removed ~12 peptides from Category 2 (including BPC-157 and TB-500) after nominators withdrew. This does NOT authorize compounding, they're in a gray zone. The July 23-24, 2026 PCAC meeting is the next key event for FDA review of BPC-157, TB-500, KPV, Semax, Epitalon, and others.
Named Chinese API Manufacturers (Upstream)
Research-grade vendors almost universally source from Chinese API manufacturers but rarely disclose the specific factory. These are the upstream suppliers visible in community research and Janoshik public test metadata:
Hangzhou Mandy Biotechnology (MandyBio)
Most visibleMost frequently named in community research. Appears directly on Janoshik public test submissions. Sells direct-to-consumer internationally. Tracked by Finnrick. Accepts crypto.
GL Biochem (Shanghai) Ltd.
Community-cited qualityFounded 1999. 8 global production sites. SPPS at mg-to-kg scale. Most frequently cited in community as a known-quality upstream source, but no confirmed direct supply to any named US vendor has been publicly documented.
Enogen (Hangzhou Enogen Biotech)
FDA Green ListGLP-1 APIs on FDA's Green List (approved for US import). Pharmaceutical-grade, one of the few Chinese manufacturers with FDA approval for specific peptides.
WuXi TIDES (WuXi AppTec)
Pharma-grade onlyMajor pharma CDMO. 100,000L+ SPPS capacity (2025). $1.65B TIDES revenue 2025 (+96% YoY). Serves global top-20 pharma companies, NOT research vendors. BIOSECURE Act risk causing some pharma clients to diversify.
Conscientia Industrial
Claims in-house SPPS manufacturing for BPC-157. Industrial supply, global shipping.
Xi'an Sonwu Biotech
BPC-157 and other peptide APIs. B2B and direct.
Third-Party Testing: Who Verifies What
Janoshik Analytical (Czech Republic)
- • ~60,000 samples/year as of April 2026
- • HPLC/MS purity, identity, and quantitative testing
- • Public results: public.janoshik.com
- • Verify any COA at janoshik.com/verify
- • Not ISO 17025 accredited (limitation)
Finnrick Analytics (US)
- • Texas-based; buys retail products, tests independently
- • ~1/3 of products tested fail basic quality checks
- • Tracks Mandybio, Limitless Life, Loti Labs, and others
- • Accepts community sample submissions
- • Site: finnrick.com
Vendors using Janoshik (confirmed COAs with verification links)
Look them up in the COA Transparency Layer, real, recycled, failed, or none.
Red flags in any COA
- • No named third-party lab
- • COAs shared across multiple vendors (sign of same batch, possibly fabricated)
- • No batch/lot number matching your vial
- • Summary numbers only, no full HPLC chromatograms
- • "Available on request" with no public database
Most Transparent Research Vendors (COA Quality)
Rankings based on community consensus as of June 2026. Not an endorsement, verify independently. For our own grade-driven, revenue-disclosed view, see the COA Lookupand PepScore rankings.
Pharma-Grade API Manufacturers (Top Tier)
These CDMOs supply branded drug makers, not research vendors, not compounding pharmacies. They represent the gold standard with GMP certification and FDA/EMA regulatory filings.
50+ years; ~two-thirds of all approved peptide APIs globally; CHF 695M revenue (2025); explicitly non-China supply chain. Supplies Ozempic/Wegovy upstream.
Founded 1952 (oldest peptide CDMO); 6 GMP sites (EU/US/India); 1,000+ peptides in GMP quality; serves 250+ pharma/biotech clients.
US-headquartered; FDA-inspected; $121.9M expansion targeting 2027 commercial scale. "China +1" alternative for pharma.
FDA-inspected (4 successful inspections); 20-30 metric tons peptide/year; 500 kg/year semaglutide and tirzepatide capacity.
Critical distinction: Bachem explicitly highlights a non-China supply chain as a selling point for pharma clients. Bachem and PolyPeptide do NOT supply research vendors or US compounding pharmacies, they serve finished-drug manufacturers exclusively.
Notable Enforcement Actions & Incidents
FDA warehouse raid ~June 18, 2025 (Memphis, TN). Founders Matthew Kawa & Jennifer Stechkober pleaded guilty Dec 10, 2025 to selling products containing testosterone labeled as SARMs and selling unapproved drugs. Site permanently offline.
Voluntary shutdown March 6, 2026. ~$7.4M/month estimated sales. Posted 3-sentence notice and went dark. Attributed to regulatory pressure and product quality concerns.
FDA Warning Letter Dec 10, 2024 for selling semaglutide and retatrutide as unapproved drugs. "Research use only" defense explicitly rejected. Site remains operational.
Washington State DOH raided Aequita in 2025 for violations including imported low-cost peptide powders and contamination risks. Partner Mochi Health paused the relationship.
FDA warning letter Dec 2025. 3 patient ER visits. Major recall July 2025. Production ceased.
Primary Sources
- FDA 503A bulk substances ↗
- FDA PCAC July 2026 meeting (BPC-157, TB-500 review) ↗
- Janoshik Analytical: public test database ↗
- Finnrick Analytics: independent vendor testing ↗
- MandyBio (Hangzhou Mandy Biotechnology) ↗
- Guardian: Labs testing thousands of unregulated substances (April 2026) ↗
- FDA import alert 66-80 / enforcement clarification ↗
You understand the chain. Now put it to work.
The supply chain is why verification matters, so verify the vendor, then compare the compound on the merits.
Educational only, not medical advice. Information compiled from public sources. Consult a licensed healthcare provider before using any compound.